Marine Soret1,2, Eve Piekarski3, Nathanaëlle Yeni3, Alain Giron4, Jacques-Antoine Maisonobe3,4, Maya Khalifé5, Claire Zaslavsky4, Marc Bertaux3, Marie-Odile Habert3,4,6, Aurélie Kas3,4. 1. Médecine Nucléaire, Hôpital Pitié-Salpêtrière, AP-HP, F-75013, Paris, France. marine.soret@aphp.fr. 2. Laboratoire d'Imagerie Biomédicale, LIB CNRS, INSERM, Sorbonne Université, CNRS, INSERM, F-75006, Paris, France. marine.soret@aphp.fr. 3. Médecine Nucléaire, Hôpital Pitié-Salpêtrière, AP-HP, F-75013, Paris, France. 4. Laboratoire d'Imagerie Biomédicale, LIB CNRS, INSERM, Sorbonne Université, CNRS, INSERM, F-75006, Paris, France. 5. Institut du Cerveau et de la Moelle Epinière, CNRS UMR 7225, INSERM U1127, Université Paris 6 UPMC UMR S1127, F-75013, Paris, France. 6. Centre d'Acquisition et Traitement des Images (CATI), Paris, France.
Abstract
PURPOSE: Integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) offers promising tools for evaluating brain disorders, including the minimization of exposure to ionizing radiation. Considering the length of scanning time with PET/MRI systems and their high sensitivity, we assumed that the activity could be reduced by one half compared with recommended activity for brain 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET exams without degrading image quality. PROCEDURES: We retrospectively simulated the reduction of injected activity (1 vs. 2 MBq/kg, [18F]FDG) in 100 patients assessed for cognitive impairment with simultaneous PET/MRI imaging. A list-mode acquisition was used to generate a 20-min image set as a reference (PETSTD) and to simulate a low-dose injection with a 10-min image (PETLD). We tested the reproducibility between PETLD and PETSTD with a blinded visual interpretation by two nuclear physicians asked to classify metabolic patterns, and a quantitative analysis conducted with regions-of-interest. Voxelwise comparisons between patients suggestive of Alzheimer's disease (AD) and frontotemporal dementia (FTD) were also conducted. RESULTS: The intra-operator agreement was high between the PETSTD and PETLD visual assessments for both readers (kappa 0.92 and 0.99). SUV ratios were strongly reproducible (intraclass correlation coefficient 0.95). The voxelwise and regional comparisons between AD vs. FTD metabolic profiles yielded very similar results with PETSTD and PETLD. CONCLUSIONS: A reduction of the [18F]FDG dose down to 1 MBq/kg is possible when performing 20-min brain PET/MRI without modifying diagnostic performance and quantitative assessments. The advantage is a significant reduction in the patient effective dose, which is non-negligible in longitudinal follow-up studies and in research protocols involving healthy volunteers.
PURPOSE: Integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) offers promising tools for evaluating brain disorders, including the minimization of exposure to ionizing radiation. Considering the length of scanning time with PET/MRI systems and their high sensitivity, we assumed that the activity could be reduced by one half compared with recommended activity for brain 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET exams without degrading image quality. PROCEDURES: We retrospectively simulated the reduction of injected activity (1 vs. 2 MBq/kg, [18F]FDG) in 100 patients assessed for cognitive impairment with simultaneous PET/MRI imaging. A list-mode acquisition was used to generate a 20-min image set as a reference (PETSTD) and to simulate a low-dose injection with a 10-min image (PETLD). We tested the reproducibility between PETLD and PETSTD with a blinded visual interpretation by two nuclear physicians asked to classify metabolic patterns, and a quantitative analysis conducted with regions-of-interest. Voxelwise comparisons between patients suggestive of Alzheimer's disease (AD) and frontotemporal dementia (FTD) were also conducted. RESULTS: The intra-operator agreement was high between the PETSTD and PETLD visual assessments for both readers (kappa 0.92 and 0.99). SUV ratios were strongly reproducible (intraclass correlation coefficient 0.95). The voxelwise and regional comparisons between AD vs. FTD metabolic profiles yielded very similar results with PETSTD and PETLD. CONCLUSIONS: A reduction of the [18F]FDG dose down to 1 MBq/kg is possible when performing 20-min brain PET/MRI without modifying diagnostic performance and quantitative assessments. The advantage is a significant reduction in the patient effective dose, which is non-negligible in longitudinal follow-up studies and in research protocols involving healthy volunteers.
Entities:
Keywords:
2-Deoxy-2-[18F]fluoro-D-glucose; Dose reduction; Magnetic resonance; Neurodegenerative disease; Positron emission tomography; SUV
Authors: Svetlana Balyasnikova; Johan Löfgren; Robin de Nijs; Yanna Zamogilnaya; Liselotte Højgaard; Barbara M Fischer Journal: Am J Nucl Med Mol Imaging Date: 2012-10-15
Authors: David Fällmar; Johan Lilja; Lena Kilander; Torsten Danfors; Mark Lubberink; Elna-Marie Larsson; Jens Sörensen Journal: Am J Nucl Med Mol Imaging Date: 2016-09-22
Authors: David Fällmar; Johan Lilja; Torsten Danfors; Lena Kilander; Victor Iyer; Mark Lubberink; Elna-Marie Larsson; Jens Sörensen Journal: Am J Nucl Med Mol Imaging Date: 2018-08-20
Authors: Marcelo A Queiroz; Gaspar Delso; Scott Wollenweber; Timothy Deller; Konstantinos Zeimpekis; Martin Huellner; Felipe de Galiza Barbosa; Gustav von Schulthess; Patrick Veit-Haibach Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240